{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gel&page=24",
    "query": {
      "intervention": "Gel",
      "page": 24
    },
    "page_size": 10
  },
  "pagination": {
    "page": 24,
    "page_size": 10,
    "total_count": 1799,
    "total_pages": 180,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gel&page=25&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Gel&page=23&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-27T03:06:51.946Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06305598",
      "title": "Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Castration-Resistant Prostate Carcinoma",
        "Metastatic Prostate Carcinoma",
        "Stage IVB Prostate Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone Scan",
          "type": "PROCEDURE"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Leuprolide Acetate",
          "type": "DRUG"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Survey Administration",
          "type": "OTHER"
        },
        {
          "name": "Testosterone Cypionate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 3,
      "start_date": "2024-12-19",
      "completion_date": "2028-03-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-07",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06305598"
    },
    {
      "nct_id": "NCT01670032",
      "title": "Vehicle Controlled Efficacy and Safety Study of Two Dose Regimens of CD07223 1.5% Topical Gel in Impetigo",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Impetigo"
      ],
      "interventions": [
        {
          "name": "Experimental: CD07223 1.5 % Topical Gel BID",
          "type": "DRUG"
        },
        {
          "name": "Experimental: CD07223 1.5% Topical Gel TID",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator: CD07223 vehicle gel BID",
          "type": "DRUG"
        },
        {
          "name": "Placebo Comparator: CD07223 vehicle gel TID",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "NovaBay Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "2 Years and older"
      },
      "enrollment_count": 328,
      "start_date": "2012-08",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2014-08-12",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 7,
      "location_summary": "Bell Gardens, California • Boca Raton, Florida • Hialeah, Florida + 4 more",
      "locations": [
        {
          "city": "Bell Gardens",
          "state": "California"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Gresham",
          "state": "Oregon"
        },
        {
          "city": "Cheraw",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01670032"
    },
    {
      "nct_id": "NCT03384784",
      "title": "Effect of Galantamine on Inflammation and Cognition",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "HIV Associated Cognitive Motor Complex"
      ],
      "interventions": [
        {
          "name": "Galantamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 63,
      "start_date": "2017-10-30",
      "completion_date": "2022-05-31",
      "has_results": true,
      "last_update_posted_date": "2024-10-17",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03384784"
    },
    {
      "nct_id": "NCT00821652",
      "title": "Randomized, Double Blind, Placebo-controlled Topical Resiquimod Adjuvant for NY-ESO-1 Protein Vaccination",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod",
          "type": "DRUG"
        },
        {
          "name": "NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nina Bhardwaj",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2009-02",
      "completion_date": "2014-12",
      "has_results": false,
      "last_update_posted_date": "2015-01-08",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00821652"
    },
    {
      "nct_id": "NCT01292447",
      "title": "A Trial of 2% Lidocaine Gel for Intrauterine Device (IUD) Insertion",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain"
      ],
      "interventions": [
        {
          "name": "2% lidocaine gel",
          "type": "DRUG"
        },
        {
          "name": "Placebo gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Women and Infants Hospital of Rhode Island",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 49 Years · Female only"
      },
      "enrollment_count": 150,
      "start_date": "2011-02",
      "completion_date": "2013-02",
      "has_results": true,
      "last_update_posted_date": "2020-09-02",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 2,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        },
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01292447"
    },
    {
      "nct_id": "NCT01659853",
      "title": "Efficacy and Safety Study Comparing CD07805/47 Gel 0.5% to Azelaic Acid Gel 15% in Subjects With Erythema of Rosacea",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Erythema",
        "Rosacea"
      ],
      "interventions": [
        {
          "name": "CD07805/47 gel 0.5%/CD07805/47 Vehicle",
          "type": "DRUG"
        },
        {
          "name": "azelaic acid gel 15%",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Galderma R&D",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 70,
      "start_date": "2012-09",
      "completion_date": "2012-12",
      "has_results": true,
      "last_update_posted_date": "2022-08-25",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 4,
      "location_summary": "Evansville, Indiana • Louisville, Kentucky • Austin, Texas + 1 more",
      "locations": [
        {
          "city": "Evansville",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Austin",
          "state": "Texas"
        },
        {
          "city": "Lynchburg",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01659853"
    },
    {
      "nct_id": "NCT04409145",
      "title": "First in Human Trial of Topical VT30 in Pts With Venous/Lymphatic Malformations Assoc With PIK3CA or TEK Gene Mutations",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Venous Malformation",
        "Lymphatic Malformation",
        "Venolymphatic Malformation"
      ],
      "interventions": [
        {
          "name": "VT30",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Venthera, Inc., a BridgeBio company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "18 Years to 60 Years"
      },
      "enrollment_count": 15,
      "start_date": "2020-10-01",
      "completion_date": "2022-04-13",
      "has_results": false,
      "last_update_posted_date": "2022-08-04",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 15,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 12 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04409145"
    },
    {
      "nct_id": "NCT00344539",
      "title": "AMA1-C1/Alhydrogel + CpG 7909 for Malaria",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Plasmodium Falciparum Malaria"
      ],
      "interventions": [
        {
          "name": "AMA1-C1/Alhydrogel®",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CPG 7909 Oligodeoxynucleotide (VaxImmune®)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 75,
      "start_date": "2005-05",
      "completion_date": "2007-01",
      "has_results": false,
      "last_update_posted_date": "2013-06-03",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 1,
      "location_summary": "Rochester, New York",
      "locations": [
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00344539"
    },
    {
      "nct_id": "NCT00002181",
      "title": "Cidofovir as a Treatment for Herpes Simplex in Patients With AIDS",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Herpes Simplex",
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "Cidofovir",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Gilead Sciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "13 Years and older"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 15,
      "location_summary": "Long Beach, California • Los Angeles, California • Oceanside, California + 10 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00002181"
    },
    {
      "nct_id": "NCT02282930",
      "title": "Pilot Study of ACTH in the Treatment of Immunoglobulin A (IgA) Nephropathy at High Risk of Progression",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Progressive IgA Nephropathy",
        "Proteinuria"
      ],
      "interventions": [
        {
          "name": "ACTH (Acthar) Gel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2015-03",
      "completion_date": "2018-06-30",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-10-27T03:06:51.946Z",
      "location_count": 4,
      "location_summary": "Palo Alto, California • Jacksonville, Florida • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02282930"
    }
  ]
}